Metformin HCL
ID: SPE2D2-21-R-0111Type: Presolicitation
Overview

Buyer

DEPT OF DEFENSEDEFENSE LOGISTICS AGENCYDLA TROOP SUPPORTPHILADELPHIA, PA, 19111, USA

PSC

DRUGS AND BIOLOGICALS (6505)

Original Source

https://sam.gov/opp/f40d1948ea214ecd93be257d692c08e7/view
Timeline
    Description

    Presolicitation DEPT OF DEFENSE DEFENSE LOGISTICS AGENCY is planning to issue a national requirements contract for Metformin HCL ER. The contract will establish a national supply source to provide Metformin HCL ER Tablets in various quantities and bottle sizes. This will be an unrestricted and fully competitive acquisition. The contract will be a firm-fixed price, requirements type contract with a one year base and four one year options. The items will be purchased by Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers through the DLA and VA prime vendor programs. The solicitation will be posted on DLA Bid Board System (DIBBS) and Sam.gov. Interested parties should contact Christopher Newman for any questions/comments. The projected solicitation date is August 2021.

    Files
    Title
    Posted
    Metformin Solicitation SPE2D221R0111.pdf
    SPE2D221R0111 0001.pdf
    Lifecycle
    Title
    Type
    Metformin HCL
    Currently viewing
    Presolicitation
    Similar Opportunities
    Metformin HCL ER
    Dept Of Defense
    Special Notice DEPT OF DEFENSE DEFENSE LOGISTICS AGENCY is procuring Metformin HCL ER. Metformin HCL ER is a drug used to treat type 2 diabetes. This procurement is being conducted by DLA TROOP SUPPORT. For more information, contact Christopher Newman at christopher.newman@dla.mil or 2157372905.
    Repaglinide
    Dept Of Defense
    Presolicitation DEPT OF DEFENSE is planning to issue a national requirements contract for Repaglinide Tablets. The contract will establish a national supply source for the purchase of Repaglinide 0.5MG, 1MG, and 2MG in 100 count bottles. This acquisition will be unrestricted and fully competitive. The contract will be a firm-fixed price, requirements type contract with a one year base and four one year options. The items listed in the schedule will be purchased by Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers through the DLA and VA prime vendor programs. Interested parties should contact Phyllis Daraio for any questions/comments. The projected solicitation date is September 2020.
    Dimethyl Fumarate DR Presolicitation
    Dept Of Defense
    The Defense Logistics Agency (DLA) is planning to issue a solicitation for a national requirements contract for Dimethyl Fumarate DR capsules, specifically 120MG capsules in 14 count bottles and 240MG capsules in 60 count bottles. This procurement aims to establish a reliable national supply source for these pharmaceutical products, which are essential for Department of Defense (DoD) customers through the DLA prime vendor program. The contract will be a firm-fixed price, requirements type contract with a one-year base period and four one-year options, emphasizing compliance with federal regulations and efficient distribution of pharmaceuticals for military healthcare. Interested parties should contact Kevin Rafferty at kevin.rafferty@dla.mil or 215-737-0907 for further inquiries, and the projected solicitation date is February 2021, with an amendment extending the offer submission deadline to October 14, 2021, at 3:00 PM EST.
    Famotidine
    Dept Of Defense
    Presolicitation DEPT OF DEFENSE is planning to issue a national requirements contract for Famotidine, a drug used to treat ulcers and gastroesophageal reflux disease (GERD). The contract will include Famotidine 20 MG tablets in various bottle sizes and Famotidine 40 MG tablets in different bottle sizes. This will be an unrestricted and fully competitive acquisition. The contract will be a firm-fixed price, requirements type contract with a one-year base and four one-year options. The contract aims to establish a national supply source to provide the items for purchase by Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers. The annual usage estimates will be provided in the solicitation. The solicitation is expected to be posted on the DLA Bid Board System (DIBBS) and SAM.gov. For any questions or comments, interested parties should contact Kristen Baraniewicz. The projected solicitation date is August 2022, but DLA reserves the right to issue the solicitation before or after that date.
    6505--Metformin SA Tablets REPACK PROGRAM
    Veterans Affairs, Department Of
    The Department of Veterans Affairs is seeking proposals for the procurement of Metformin SA Tablets through a repack program, as outlined in solicitation 36E79725R0003. Bidders are required to meet specific packaging standards, including the use of safety-caps that can be converted or deshelled, with bottles having a minimum size of 120cc and a cylindrical design that accommodates a label of specified dimensions. This procurement is critical for ensuring the availability of essential pharmaceutical products for veteran populations, adhering to FDA regulations and maintaining healthcare quality. Interested parties must submit their offers by January 28, 2025, at 2:30 PM CST, and can direct inquiries to Senior Contract Specialist Teresa Hussain at teresa.hussain@va.gov.
    Valsartan
    Dept Of Defense
    Presolicitation DEPT OF DEFENSE is planning to issue a national requirements contract for Valsartan, a drug used to treat high blood pressure and heart failure. The contract will include Valsartan tablets in various strengths and quantities. It will be a firm-fixed price, requirements type contract with a one year base and four one year options. The contract aims to establish a national supply source for Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers. The solicitation will be posted on the DLA Bid Board System and beta.SAM.gov, with a projected solicitation date in June 2021. Interested parties should contact Christopher Newman for more information.
    Pantoprazole DR Tablets
    Dept Of Defense
    Presolicitation DEPT OF DEFENSE Pantoprazole DR Tablets: The Defense Logistics Agency is planning to issue a national requirements contract for Pantoprazole DR Tablets. These tablets, available in 20MG and 40MG strengths, will be provided in 90 and 1000 count bottles. The contract will be a firm-fixed price, requirements type contract with a one year base and four one year options. The tablets will be purchased by the Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers through the DLA and VA prime vendor programs. The annual usage estimates will be provided in the solicitation. Interested parties can find more information on the DLA Bid Board System and Beta Sam.Gov websites. The solicitation is projected to be issued in September 2021.
    Rizatriptan Benzoate
    Dept Of Defense
    Presolicitation DEPT OF DEFENSE is planning to issue a national requirements contract for Rizatriptan Benzoate tablets. The contract will establish a national supply source to provide the items listed in the schedule for purchase by Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers. The contract will be a firm-fixed price, requirements type contract with a one year base and four one year options. The solicitation will be posted on the DLA Bid Board System and SAM.gov. Interested parties should contact Keith Ryales for any questions/comments. The projected solicitation date is June 2022.
    Bicalutamide 50MG tablets
    Dept Of Defense
    The Defense Logistics Agency (DLA) is issuing a solicitation for a national requirements contract for Bicalutamide 50MG tablets, available in bottle counts of 30 and 500. The procurement aims to establish a reliable supply source for these pharmaceutical items, which are critical for various Department of Defense and other federal health programs, including the Department of Veterans Affairs and the Indian Health Service. This unrestricted and fully competitive acquisition will be a firm-fixed price contract with a one-year base and four one-year options, with proposals due by January 24, 2025. Interested parties can reach out to Keith Ryales at keith.ryales@dla.mil or 215-737-9199 for further inquiries and are encouraged to monitor the DLA Bid Board System and SAM.gov for updates on the solicitation.
    Rabeprazole Sodium Delayed Release Tablets
    Dept Of Defense
    Presolicitation DEPT OF DEFENSE is planning to issue a national requirements contract for Rabeprazole Sodium Delayed Release Tablets. The tablets will be used for medical purposes and will be available in 30, 90, and 500 count bottles. The contract will be a firm-fixed price, requirements type contract with a one year base and four one year options. The contract aims to establish a national supply source to provide the tablets for purchase by Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers. Interested parties should contact Phyllis Daraio for more information. The projected solicitation date is February 2020.